Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
815 studies found for:    Herceptin
Show Display Options
Rank Status Study
1 Terminated Neoadjuvant Herceptin in Patients With Breast Cancer
Intervention: Drug: Herceptin
2 Completed
Has Results
MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer
Condition: Breast Neoplasms
Intervention: Drug: MM-111 + Herceptin
3 Suspended Early Predictor of Herceptin Cardio Toxicity in Breast Cancer Patients
Condition: Breast Cancer
Intervention: Drug: Herceptin
4 Recruiting Perioperative Chemotherapy With Herceptin For Potentially Resectable HER-2 Positive Gastric Cancer With Liver Metastasis
Conditions: HER-2 Positive Gastric Cancer;   Liver Metastasis
Interventions: Drug: Oxaliplatin plus Capecitabine;   Drug: Herceptin
5 Recruiting microRNA of Human Epidermal Growth Factor Receptor 2 (HER2)Positive Patient Treated With Herceptin
Condition: Breast Cancer
Interventions: Drug: Capecitabine;   Drug: Trastuzumab
6 Completed
Has Results
Neoadjuvant Herceptin for Ductal Carcinoma In Situ of the Breast
Condition: Ductal Carcinoma In Situ
Intervention: Drug: Herceptin (Trastuzumab)
7 Active, not recruiting A Study to Compare the Effect of SB3 and Herceptin® in Women With HER2 Positive Breast Cancer
Condition: HER2 Positive Early or Locally Advanced Breast Cancer
Interventions: Drug: Herceptin (trastuzuamb);   Drug: SB3 (proposed trastuzumab biosimilar)
8 Active, not recruiting Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer
Condition: Breast Cancer
Intervention: Radiation: Trastuzumab
9 Completed
Has Results
An Observational Time and Motion Study of Trastuzumab Subcutaneous (SC) and Intravenous (IV) Formulations in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (EBC)
Condition: Breast Cancer
Intervention: Drug: Trastuzumab
10 Completed
Has Results
A Safety and Efficacy Study of BCD-022 With Paclitaxel Compared to Herceptin With Paclitaxel in HER2-Positive Metastatic Breast Cancer Patients
Condition: Human Epithelial Receptor (HER)-2 Positive Breast Cancer
Interventions: Drug: Trastuzumab;   Drug: Paclitaxel
11 Recruiting Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+ Esophageal Carcinoma
Condition: Esophageal Carcinoma
Intervention: Drug: Pertuzumab, trastuzumab
12 Completed Real World Efficiency of Trastuzumab in Early Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Trastuzumab
13 Active, not recruiting Study of Efficacy and Safety of Myl1401O + Taxane vs Herceptin©+ Taxane for 1st Line, Met. Br. Ca.
Condition: Breast Cancer
Interventions: Biological: Trastuzumab;   Biological: HERMyl 1401O Trastuzumab;   Drug: Paclitaxel;   Drug: Docetaxel
14 Not yet recruiting Combination Trastuzumab With Expanded Natural Killer Cells for Treating HER2-positive Gastric Cancer
Condition: Gastric Cancer
Intervention: Drug: Trastuzumab + NK cells
15 Completed Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer
Condition: Urologic Neoplasms
Interventions: Drug: Trastuzumab;   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Gemcitabine
16 Recruiting Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis
Conditions: Metastatic Breast Cancer;   Carcinomatous Meningitis
Intervention: Drug: Trastuzumab
17 Unknown  Trastuzumab Optimization Trial in Breast Cancer
Condition: Metastatic or Locally Advanced Breast Cancer
Intervention: Drug: trastuzumab
18 Active, not recruiting A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Trastuzumab (Herceptin) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer
Condition: Breast Cancer
Interventions: Drug: 5-Fluorouracil;   Drug: Cyclophosphamide;   Drug: Docetaxel;   Drug: Epirubicin;   Drug: Herceptin IV;   Drug: Herceptin SC
19 Terminated
Has Results
A Study of Herceptin (Trastuzumab) Monotherapy in Patients With Metastatic Urothelial Cancer
Condition: Urinary Tract Cancer
Intervention: Drug: trastuzumab
20 Terminated Trastuzumab Therapy in Non-Small Cell Lung Cancer Patients
Intervention: Drug: Trastuzumab (Herceptin)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.